Jump to: navigation, search

Chronic myelomonocytic leukemia

34 bytes added, 08:40, 5 November 2017
no edit summary
*[ NCCN Guidelines - Myelodysplastic Syndromes]
=UntreatedFirst-line therapy=
==Azacitidine monotherapy {{#subobject:3235e3|Regimen=1}}==
# Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. Epub 2017 May 9. [ link to original article] '''contains verified protocol''' [ PubMed]
=Maintenanceafter first-line therapy=
==Azacitidine monotherapy {{#subobject:2471cc|Regimen=1}}==
LookupUsers, editors, emailconfirmed

Navigation menu